Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Icosapent Ethyl→

Icosapent Ethyl PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
86227-47-6
Molecular formula
C22H34O2
Molecular weight
330.51 g/mol
Drug class
Ethyl ester of eicosapentaenoic acid (EPA)omega-3 fatty acid lipid-modifying agent
Mechanism of action
Icosapent ethyl is hydrolysed to EPA. EPA may reduce hepatic very-low-density lipoprotein triglyceride synthesis and/or secretion and enhance triglyceride clearance; additional anti-inflammatory and membrane effects may contribute, but the precise cardiovascular risk-reduction mechanism is not fully established.
Indications / reported uses
  • Adjunct to maximally tolerated statin therapy to reduce triglyceride levels in adults with severe hypertriglyceridaemia
  • Adjunct to statin therapy to reduce risk of myocardial infarction, stroke, coronary revascularisation and unstable angina requiring hospitalisation in eligible adults with elevated triglycerides and established cardiovascular disease or diabetes plus additional risk factors

Sources: US DailyMed — VASCEPA (icosapent ethyl) · US FDA prescribing information · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Ethyl ester of eicosapentaenoic acid (EPA); omega-3 fatty acid lipid-modifying agent

Mechanism of action

Icosapent ethyl is hydrolysed to EPA. EPA may reduce hepatic very-low-density lipoprotein triglyceride synthesis and/or secretion and enhance triglyceride clearance; additional anti-inflammatory and membrane effects may contribute, but the precise cardiovascular risk-reduction mechanism is not fully established.

General use cases

  • Adjunct to maximally tolerated statin therapy to reduce triglyceride levels in adults with severe hypertriglyceridaemia
  • Adjunct to statin therapy to reduce risk of myocardial infarction, stroke, coronary revascularisation and unstable angina requiring hospitalisation in eligible adults with elevated triglycerides and established cardiovascular disease or diabetes plus additional risk factors

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Icosapent Ethyl PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Icosapent Ethyl Permitted Daily Exposure (PDE) report (the Icosapent Ethyl PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Icosapent Ethyl Occupational Exposure Limit (OEL) report (the Icosapent Ethyl OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.